Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foselutoclax - UNITY Biotechnology

Next Previous
X
Search
Drug Profile

Foselutoclax - UNITY Biotechnology

Alternative Names: BM-962; UBX-1325

Latest Information Update: 07 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentage Pharma
  • Developer UNITY Biotechnology
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Wet age-related macular degeneration
  • No development reported Diabetic retinopathy

Most Recent Events

  • 04 Nov 2024 UNITY Biotechnology conducted a type-C meeting with US FDA for foselutoclax in Diabetic macular oedema
  • 04 Nov 2024 UNITY Biotechnology plans a pivotal non-inferiority trial for Diabetic macular oedema
  • 01 Mar 2024 UNITY Biotechnology has patent protection for UBX 1325 in USA, Canada, Europe, New Zealand, Hong Kong, Mexico, South Korea, and South Africa

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top